PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies
Authors:
- 25 February 2013
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (11) , 4339-4344
Abstract
Despite their nearly universal activation of mammalian target of rapamycin (mTOR) signaling, glioblastomas (GBMs) are strikingly resistant to mTOR-targeted therapy. We analyzed GBM cell lines, patient-derived tumor cell cultures, and clinical samples from patients in phase 1 clinical trials, and find that the promyelocytic leukemia (PML) gene mediates resistance to mTOR-targeted therapies. Direct mTOR inhibitors and EGF receptor (EGFR) inhibitors that block downstream mTOR signaling promote nuclear PML expression in GBMs, and genetic overexpression and knockdown approaches demonstrate that PML prevents mTOR and EGFR inhibitor-dependent cell death. Low doses of the PML inhibitor, arsenic trioxide, abrogate PML expression and reverse mTOR kinase inhibitor resistance in vivo, thus markedly inhibiting tumor growth and promoting tumor cell death in mice. These results identify a unique role for PML in mTOR and EGFR inhibitor resistance and provide a strong rationale for a combination therapeutic strategy to overcome it.Keywords
This publication has 38 references indexed in Scilit:
- A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenanceNature Medicine, 2012
- Translation‐dependent mechanisms lead to PML upregulation and mediate oncogenic K‐RAS‐induced cellular senescenceEMBO Molecular Medicine, 2012
- Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy ResistanceCancer Discovery, 2011
- Pml represses tumour progression through inhibition of mTOREMBO Molecular Medicine, 2011
- EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic TherapyScience Signaling, 2009
- Fyn and Src Are Effectors of Oncogenic Epidermal Growth Factor Receptor Signaling in Glioblastoma PatientsCancer Research, 2009
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- PML targeting eradicates quiescent leukaemia-initiating cellsNature, 2008
- Identification of a tumour suppressor network opposing nuclear Akt functionNature, 2006